Improvement of time in therapeutic range with warfarin by pharmaceutical intervention

被引:5
|
作者
Viquez-Jaikel, Alvaro [1 ,2 ]
Hall-Ramirez, Victoria [3 ]
Ramos-Esquivel, Allan [4 ]
机构
[1] Hosp San Juan Dios, Unidad Atenc Farmaceut, Caja Costarricense Seguro Social, San Jose, Costa Rica
[2] Univ Autonoma Ciencias Med, Farm Hospitalaria, San Jose, Costa Rica
[3] Univ Costa Rica, Ctr Informac Medicamentos, Escuela Farm, San Jose, Costa Rica
[4] Univ Costa Rica, Dept Farmacol, Escuela Med, POB 2060, San Jose, Costa Rica
关键词
Anticoagulants; Costa Rica; Drug monitoring; International normalized ratio; Pharmaceutical intervention; Warfarin; NORMALIZED RATIO CONTROL; ATRIAL-FIBRILLATION; ORAL ANTICOAGULANT; QUALITY;
D O I
10.1007/s11096-016-0403-5
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background Anticoagulation therapy with warfarin is highly effective for prevention and treatment of thromboembolic disorders. Nevertheless, its management is challenging especially in developing countries, where the medical access is difficult and patient education is poor. Objective To determine the effect of pharmaceutical intervention (PI) on the time in therapeutic range (TTR) of a group of anticoagulated patients from our referral center. Method A group of consecutive outpatients previously treated by usual medical care underwent PI. The intervention consisted in the identification and avoidance of food and drug interactions, the confection of medication schedule charts and education to patients regarding side effects and drug monitoring. Mean TTR before and after PI was compared through the Wilcoxon test for repeated measures. Regression analyses were performed to assess the relationship between a TTR level under 65% and potential explanatory variables. Results Mean TTR before PI was 37.4 +/- 23.5% and after PI it raised to 67.0 +/- 24.9%. Mean change in TTR was +29.5% (95% CI 14.5-44.6; p < 0.001). Before PI only 4 patients had TTR values above 65%, in contrast to 18 patients after PI. Conclusion Our findings support the efficacy of PI to improve TTR values in patients treated with warfarin.
引用
收藏
页码:41 / 44
页数:4
相关论文
共 50 条
  • [1] Improvement of time in therapeutic range with warfarin by pharmaceutical intervention
    Alvaro Víquez-Jaikel
    Allan Victoria Hall-Ramírez
    International Journal of Clinical Pharmacy, 2017, 39 : 41 - 44
  • [2] Apixaban Compared With Warfarin for Stroke Prevention in Atrial Fibrillation Implications of Time in Therapeutic Range
    Gallego, Pilar
    Antonio Vilchez, Juan
    Lane, Deirdre A.
    CIRCULATION, 2013, 127 (22) : 2163 - 2165
  • [3] Time in therapeutic range values of patients using warfarin and factors that influence time in therapeutic range
    Asarcikli, Lale Dinc
    Kafes, Habibe
    Sen, Taner
    Ipek, Esra Gucuk
    Cebeci, Muhammet
    Gul, Murat
    Kanat, Selcuk
    Temizhan, Ahmet
    TURK KARDIYOLOJI DERNEGI ARSIVI-ARCHIVES OF THE TURKISH SOCIETY OF CARDIOLOGY, 2021, 49 (06): : 463 - 473
  • [4] Pharmaceutical Care Increases Time in Therapeutic Range of Patients With Poor Quality of Anticoagulation With Warfarin
    Marcatto, Leiliane Rodrigues
    Sacilotto, Luciana
    Tavares, Leticia Camargo
    Facin, Mirella
    Olivetti, Natalia
    Cassaro Strunz, Celia Maria
    Costa Darrieux, Francisco Carlos
    Scanavacca, Mauricio Ibrahim
    Krieger, Jose Eduardo
    Pereira, Alexandre Costa
    Junior Lima Santos, Paulo Caleb
    FRONTIERS IN PHARMACOLOGY, 2018, 9
  • [5] Quality Improvement Program Improves Time in Therapeutic Range for Hemodialysis Recipients Taking Warfarin
    Blum, Daniel
    Beaubien-Souligny, William
    Battistella, Marisa
    Tseng, Eric
    Harel, Ziv
    Nijjar, Jaspreet
    Nazvitch, Elena
    Silver, Samuel A.
    Wald, Ron
    KIDNEY INTERNATIONAL REPORTS, 2020, 5 (02): : 159 - 164
  • [6] Evaluating time in therapeutic range for hemodialysis patients taking warfarin
    Quinn, Laura M.
    Richardson, Robert
    Canneron, Karen J.
    Battistella, Marisa
    CLINICAL NEPHROLOGY, 2015, 83 (02) : 80 - 85
  • [7] Warfarin therapeutic monitoring: is 70% time in the therapeutic range the best we can do?
    Lader, E.
    Martin, N.
    Cohen, G.
    Meyer, M.
    Reiter, P.
    Dimova, A.
    Parikh, D.
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2012, 37 (04) : 375 - 377
  • [8] The awareness, efficacy, safety, and time in therapeutic range of warfarin in the Turkish population: WARFARIN-TR
    Celik, Ahmet
    Izci, Servet
    Kobat, Mehmet Ali
    Ates, Ahmet Hakan
    Cakmak, Abdulkadir
    Cakilli, Yasin
    Yilmaz, Mehmet Birhan
    Zoghi, Mehdi
    ANATOLIAN JOURNAL OF CARDIOLOGY, 2016, 16 (08) : 595 - 600
  • [9] Determination of Factors Affecting Time in Therapeutic Range in Patients on Warfarin Therapy
    Turen, Sevda
    Turen, Selahattin
    BIOLOGICAL RESEARCH FOR NURSING, 2023, 25 (01) : 170 - 178
  • [10] Identification of environmental and genetic factors that influence warfarin time in therapeutic range
    Botton, Mariana R.
    Viola, Patricia P.
    Meireles, Mariana R.
    Bruxel, Estela M.
    Zuchinali, Priccila
    Bandinelli, Eliane
    Rohde, Luis E.
    Leiria, Tiago L. L.
    Salamoni, Joyce Y. Y.
    Garbin, Arthur P.
    Hutz, Mara H.
    GENETICS AND MOLECULAR BIOLOGY, 2020, 43 (01)